SALT LAKE CITY– The first case of a rare blood-clotting condition thought to be linked to the Johnson & & Johnson COVID-19 vaccine has been identified in Utah.A male patient was just recently identified with vaccine-induced Thrombotic Thrombocytopenia, likewise understood as VITT, at the University of Utah Hospital, U. health authorities stated in a Wednesday news release.The client, who is under the age of 50, was treated and is now recuperating at house, according to Dr. Yazan Abou-Ismail, an assistant teacher of medication in the Division of Hematology at the University of Utah.” He continues to do well and feel well,” Abou-Ismail said at a Wednesday news conference about the case.The blood clot condition led to an across the country pause on administration of the Johnson & & Johnson vaccine last month after 6 cases were reported among over 6 million people who received the vaccine. Medical professionals followed up with him several days earlier and he continues to enhance, Abou-Ismail said.So far, the Centers for Disease Control and Prevention has actually verified 17 cases of VITT in the United States suspected to be linked to the Johnson & & Johnson vaccine out of about 8 million dosages administered, according to Abou-Ismail.
- Researchers Analyze: How Accurate Were Early Expert Predictions on COVID-19? – SciTechDaily
- Hawaii reports 1 new coronavirus-related death and 64 additional infections – Honolulu Star-Advertiser